Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis

被引：0

作者：

Valis, M. ^{[1
]}

Haluskova, S. ^{[1
]}

机构：

[1] Neurol Klinika LF UK FN Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic

来源：

CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2021年 / 84卷 / 05期

关键词：

multiple sclerosis; treatment; antibodies monoclonal; ofatumumab; DISEASE-ACTIVITY; NO EVIDENCE; B-CELLS; OCRELIZUMAB; THERAPIES; ANTIBODY;

D O I：

10.48095/cccsnn2021436

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

There has been tremendous progress in the treatment of MS over recent years. The concept of early treatment to achieve better outcomes in MS has clearly emerged, fully supported by long-term data. The effi cacy of anti-CD20 monoclonal antibodies in the treatment of MS has been confi rmed in clinical trials. Ofatumumab is a fully-humanized anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing-remitting MS. Ofatumumab showed high effi cacy and a favorable safety profile in phase III clinical trials, offering the first B-cell therapy that can be subcutaneously self-administered at home.

引用

页码：436 / 440

页数：5

共 50 条

[21] Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis [J].

Osherov, Michael ;

Milo, Ron .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) :1037-1047

[22] New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis [J].

Vidal-Jordana, Angela .

NEUROLOGIC CLINICS, 2018, 36 (01) :173-+

[23] Ofatumumab in the treatment of multiple sclerosis - A summary of preclinical and clinical data [J].

Klehmet, Juliane ;

Bopp, Tobias .

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2024,

[24] Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis [J].

Samjoo, Imtiaz A. ;

Klotz, Luisa ;

Giovannoni, Gavin ;

Drudge, Christopher ;

Haltner, Anja ;

Worthington, Evelyn ;

Zhao, Melody ;

Brennan, Roisin ;

Haring, Dieter A. ;

Cameron, Chris ;

Adlard, Nicholas .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 66

[25] Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis [J].

Onder, Halil .

TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (02) :105-106

[26] Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis [J].

Mariottini, Alice ;

Nozzoli, Chiara ;

Carli, Ilaria ;

Landi, Filippo ;

Gigli, Valentina ;

Repice, Anna Maria ;

Ipponi, Alessandra ;

Cecchi, Michele ;

Boncompagni, Riccardo ;

Saccardi, Riccardo ;

Massacesi, Luca .

NEUROLOGICAL SCIENCES, 2024, 45 (07) :3379-3387

[27] Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data [J].

Ruggieri, Serena ;

Quartuccio, Maria Esmeralda ;

Prosperini, Luca .

DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2022, 12 :61-73

[28] New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis [J].

Fox, Edward J. ;

Rhoades, Robert W. .

CURRENT OPINION IN NEUROLOGY, 2012, 25 :S11-S19

[29] Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study [J].

El Mahdaoui, Sahla ;

Christensen, Jeppe Romme ;

Magyari, Melinda ;

Wandall-Holm, Malthe Faurschou ;

Sellebjerg, Finn .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68

[30] Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis [J].

Schweitzer, Finja ;

Laurent, Sarah ;

Fink, Gereon R. ;

Barnett, Michael H. ;

Reddel, Stephen ;

Hartung, Hans-Peter ;

Warnke, Clemens .

CURRENT OPINION IN NEUROLOGY, 2019, 32 (03) :305-312

← 1 2 3 4 5 →